Highlights of the updated Dutch evidence‐ and consensus‐based guideline on psoriasis 2017

Kraaij, G. E. van der; Balak, Deepak M W; Busard, C.; Cranenburgh, O.D. van; Chung, Yan Ee Lynette; Driessen, R.J.B.; Groot, Marjan de; Jong, E.M.G.J. de; Kemperman, P. M. J. H.; Kort, W. J. A. de; Karsch, Saskia A. T.; Lamberts, Aniek; Lecluse, L.L.A.; Lümig, P.P.M. van; Menting, S.P.; Prens, Errol P.; Reek, J.M.P.A. van den; Seyger, M.M.B.; Thio, Hok Bing; Veldkamp, W. R.; Wakkee, Marlies; Nast, Alexander; Jacobs, Annelies; Rosumeck, Stefanie; Spuls, Phyllis I.

doi:10.1111/bjd.17198

Cited by 21 publications

(17 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, this was described in the NICE assessment of certolizumab pegol (NICE 2019 [ 31 ]). The guidelines allow for the use of other TNF-α inhibitors in that period (ACR 2020 [ 26 ], Dutch Guidelines [ 27 ]), and recommend discontinuing the use of drugs from other therapeutic groups ( Table 3 ) (ACR 2020 [ 26 ]).…”

Section: Resultsmentioning

confidence: 99%

“…According to guidelines, treatment discontinuation during pregnancy is recommended in the case of secukinumab and ustekinumab (ACR 2020 [ 26 ]). Adalimumab, infliximab and etanercept should not be used during the 2 nd and 3 rd trimester of pregnancy (BAD 2020 [ 25 ], ACR 2020 [ 26 ], Dutch Guidelines [ 27 ]). The guidelines do not make references to the use of risankizumab, guselkumab, tildrakizumab and brodalumab by pregnant patients ( Table 4 ).…”

Section: Resultsmentioning

confidence: 99%

“…a system for rating the quality of a body of evidence [ 24 ]. Finally, 5 documents were selected for further works: the latest version of guidelines issued by the British Association of Dermatologists in 2020 (BAD 2020 [ 25 ]), guidelines issued by the American College of Rheumatology in 2020 (ACR 2020 [ 26 ] – included as the widest document on the use of biological drugs), Dutch guidelines: Kraaij 2019 [ 27 ], Latin American Clinical practice guidelines: Kogan 2019 [ 28 ] and German guidelines: Nast 2018 [ 29 ]. Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) [ 24 ] methodology was used to assess the body of evidence on which the guidelines and recommendations were based.…”

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

The use of biological drugs in psoriasis patients prior to pregnancy, during pregnancy and lactation: a review of current clinical guidelines

Owczarek¹,

Walecka²,

Lesiak³

et al. 2020

pdia

View full text Add to dashboard Cite

Introduction Information on the possibility of using biological drugs in psoriasis patients planning to conceive, patients who are pregnant or during lactation is limited. Aim Presenting recommendations published in clinical guidelines regarding the use of biological drugs – adalimumab, brodalumab, certolizumab pegol, etanercept, guselkumab, infliximab, ixekizumab, risankizumab, secukinumab, tildrakizumab, and ustekinumab, by psoriasis patients in the period of planning pregnancy, during pregnancy or during lactation. Material and methods The paper was based on a comprehensive review of over 40 websites of HTA agencies, dermatological associations worldwide and medical databases (PubMed, Embase), the objective of which was to identify clinical guidelines relating to biological treatment of women of childbearing potential, published after 2018, which used GRADE – a system for rating the quality of a body of evidence. Findings Certolizumab pegol is recommended in women who are planning to conceive. Furthermore, guidelines indicate other TNF-α inhibitors as possible treatment. Certolizumab pegol is also recommended as first-line treatment in pregnant patients. Furthermore, for trimesters 2 and 3, guidelines allow using other TNF-α inhibitors. Treatment with secukinumab and ustekinumab should be discontinued when planning pregnancy or when pregnancy was diagnosed. Biological treatment during pregnancy and lactation (continuation or initiation of treatment) can be used only after an analysis of risks and benefits has been conducted. Conclusions TNF-α inhibitors seem to be the safest and most researched biological drugs used in psoriasis treatment of patients planning to conceive, during pregnancy or lactation. Given its non-existent or minimal placental permeability, most likely the safest alternative is certolizumab pegol.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

The use of biological drugs in psoriasis patients prior to pregnancy, during pregnancy and lactation: a review of current clinical guidelines

Owczarek¹,

Walecka²,

Lesiak³

et al. 2020

pdia

View full text Add to dashboard Cite

show abstract

“…If necessary, ciclosporin treatment can be continued with close follow‐up, preferably together with an obstetrician 267,268 . Ciclosporin is transferred into breastmilk; therefore, ciclosporin use is contraindicated during breastfeeding.…”

Section: Guidance For Specific Clinical and Comorbid Situationsmentioning

confidence: 99%

EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 2: specific clinical and comorbid situations

Nast

Smith

Spuls

et al. 2021

Acad Dermatol Venereol

Self Cite

125

141

View full text Add to dashboard Cite

This evidence‐ and consensus‐based guideline on the treatment of psoriasis vulgaris was developed following the EuroGuiDerm Guideline and Consensus Statement Development Manual. The second part of the guideline provides guidance for specific clinical and comorbid situations such as treating psoriasis vulgaris patient with concomitant psoriatic arthritis, concomitant inflammatory bowel disease, a history of malignancies or a history of depression or suicidal ideation. It further holds recommendations for concomitant diabetes, viral hepatitis, disease affecting the heart or the kidneys as well as concomitant neurological disease. Advice on how to screen for tuberculosis and recommendations on how to manage patients with a positive tuberculosis test result are given. It further covers treatment for pregnant women or patients with a wish for a child in the near future. Information on vaccination, immunogenicity and systemic treatment during the COVID‐19 pandemic is also provided.

show abstract

“…Considering certolizumab, as of writing this chapter, it is ostensibly the only discovered biological agent that fails to cross the maternal-placental barrier, and no adverse or teratogenic consequences were discovered if taken while pregnant [69]. In Table 4, we illustrate the minimal time interval suggested between discontinuing the medication and child conception [82].…”

Section: Biological Therapies and Pregnancymentioning

confidence: 99%

Medical Management of Chronic Plaque Psoriasis in the Modern Age

Mitrea¹,

Florian²

2019

Healthcare Access - Regional Overviews [Working Title]

View full text Add to dashboard Cite

Despite its frequency, psoriasis is still a difficult pathology to manage, in no small part due to the wide number of therapeutic choices available. These range from topical medicine to systemic drugs to more targeted agents such as biological therapies. All medical personnel involved in the treatment of psoriasis patients should be aware of these methods and apply them accordingly. Even though all patients may benefit from specific treatment options, these differ in regard to posology, monitoring, interactions and contraindications. Moreover, due to the adverse effects and drug interactions of some of these agents, not all patients are suitable candidates for each of therapies discussed. Therefore, nurses, trainees, general practitioners and dermatologists must carefully select the most appropriate therapy based on the characteristics of each patient, severity of the pathology, comorbidities and coexistent medications. This review aims to offer an updated, pragmatic insight into the modern management of patients with moderate-tosevere psoriasis.

show abstract

Highlights of the updated Dutch evidence‐ and consensus‐based guideline on psoriasis 2017

Abstract: Linked Comment: https://doi.org/10.1111/bjd.17390.

Cited by 21 publications

References 55 publications

The use of biological drugs in psoriasis patients prior to pregnancy, during pregnancy and lactation: a review of current clinical guidelines

The use of biological drugs in psoriasis patients prior to pregnancy, during pregnancy and lactation: a review of current clinical guidelines

EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 2: specific clinical and comorbid situations

Medical Management of Chronic Plaque Psoriasis in the Modern Age

Contact Info

Product

Resources

About